ArticleNPJ breast cancer2018
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.
Article in NPJ breast cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Adiposity and risk of breast cancer in 280 000 Chinese women: a prospective cohort study.International journal of epidemiology · 2026Observational
- Causal relationship between blood metal levels and breast cancer risk: a Mendelian randomization study in East Asian populations.Discover oncology · 2025Article
- TET Enzymes and 5hmC Levels in Carcinogenesis and Progression of Breast Cancer: Potential Therapeutic Targets.International journal of molecular sciences · 2023Review
- TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.Breast cancer research : BCR · 2023Article
- A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.British journal of cancer · 2023Article
- Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.BMC medical genomics · 2022Article
- Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients.HGG advances · 2022Article
- Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.Cancer reports (Hoboken, N.J.) · 2021Article
- Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China.Journal of oncology · 2021Article
- Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development".Handbook of experimental pharmacology · 2021Article
- Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program.Breast care (Basel, Switzerland) · 2020Article
- Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence.Journal of breast cancer · 2020Article
- Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.Medical sciences (Basel, Switzerland) · 2020Review
- Cellular and molecular architecture of hematopoietic stem cells and progenitors in genetic models of bone marrow failure.JCI insight · 2020Article
- A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.Cancer medicine · 2020Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is an increasing problem in Asia, with a higher proportion of premenopausal patients who are at higher risk of recurrence. Targeted sequencing was performed on DNA extracted from primary tumor specimens of 63 premenopausal Asian patients who relapsed after initial diagnosis of non-metastatic breast cancer. The most prevalent alterations included:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.